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The treatment of melanoma by targeted inhibition of the mutated kinase BRAF with
small molecules only temporarily suppresses metastatic disease. In the face of chemical
inhibition tumor plasticity, both innate and adaptive, promotes survival through the
biochemical and genetic reconfiguration of cellular pathways that can engage proliferative
and migratory systems. To investigate this process, high-resolution mass spectrometry
was used to characterize the phosphoproteome of this transition in vitro. A simple and
accurate, label-free quantitative method was used to localize and quantitate thousands
of phosphorylation events. We also correlated changes in the phosphoproteome with
the proteome to more accurately determine changes in the activity of regulatory kinases
determined by kinase landscape profiling. The abundance of phosphopeptides with
sites that function in cytoskeletal regulation, GTP/GDP exchange, protein kinase C, IGF
signaling, and melanosome maturation were highly divergent after transition to a drug
resistant phenotype.
Keywords: phosphoproteomics, BRAF, drug resistance, vemurafenib, kinases, label-free quantitation, mass
spectrometry
Introduction
In melanoma, coding mutations in the mitogen-activated kinase pathway (MAPK) (e.g., BRAF
and RAS) are common and contribute to disease severity (1). In cutaneous melanoma, BRAF is
mutated in ~70% of cases and correlates with poorer prognosis and aggressive disease (2, 3). The
mutant BRAF protein is a hyperactive serine/threonine-protein kinase that directs signaling through
MEK1/2 to phosphorylate the MAPK ERK1/2 and drive cell proliferation and tumor growth. In
recent years, a high-therapeutic value has been attained by targeted inhibition of the mutated
BRAF protein with selective inhibitors (e.g., vemurafenib and dabrafenib) (4–6). Vemurafenib and
dabrafenib effectively reduce signaling through the MAPK pathway, resulting in disease regression
(~85%) and progression free survival for ~5–6months [reviewed in Ref. (7)], after which almost all
treated patients develop drug resistant, progressive disease (5).
Several mechanisms for intrinsic and acquired resistance have been detected in vivo and in vitro
and this has been extensively reviewed (7–9). Relapses in melanoma involve mechanisms that
reprogram signaling pathways to bypass inhibition and reactivate the ERK1/2 signaling hub (10).
For example, the up-regulation of receptor tyrosine kinases (RTKs), platelet derived growth factor
(PDGF), epidermal growth factor receptor (EGFR), and insulin-like growth factor 1 receptor
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(IGF-1R) can drive cell survival signals through the PI3K/AKT
pathway (11–13). Alternative pathways that reactivate ERKduring
targeted therapy utilize the multimeric properties of RAF signal-
ing complexes and also occur in BRAF wild-type cells. BRAF
inhibitors have been shown to drive the formation of alternative
RAFdimers able to phosphorylateMEKand induceERK signaling
(14–17). In drug resistant patients, up-regulation and splicing of
MAPK signaling components [CRAF, BRAF, or the MAP3K8
(COT)] provide alternative mechanisms for the reactivation of
ERK1/2 signaling (18–20). In response to the microenvironment,
phenotypic switching can also occur based upon intrinsic tumor
heterogeneity and lead to resistance to therapy (21). For example,
paracrine signaling from stromal cells that secrete hepatocyte
growth factor (HGF) reestablish the MAPK pathway in BRAF
mutated cells by activating the RTK MET (22). Independent of
the MAPK pathway, low expression of the melanocyte transcrip-
tional network driver microphthalmia-associated transcription
factor (MITF) associates with drug resistance and a more inva-
sive, less proliferative phenotype (23, 24). This and the fact that
MAPK inhibitors can themselves drive an invasive phenotype
(25) indicate that inter-tumor plasticity allowsmelanoma to evade
complete growth arrest in the face of MAPK inhibition.
The discovery of these mechanisms and others [reviewed in
Ref. (8)] has established opportunities for novel melanoma treat-
ment. The design of more effective co-inhibitory-based therapies
could represent an improved strategy to prevent the acquired
resistant phenotypes currently found in the clinic. In most cases,
combination therapies in which BRAF inhibition is paired with
inhibitors of the well establish mediators of resistance (PI3K,
MEK, HGF, and IGF-R1) is showing promise (12, 26, 27). Because
kinases (ERK1/2, IGF-R1, MEK, PI3K) provide key signaling
hubs that orchestrate biochemical processes in drug resistant
melanoma, characterizing their global activity profiles will aid
the design of novel therapies. Kinase activity can be mapped by
measuring the abundance of substrates using phosphoproteomic
methods that combine phosphopeptide enrichment with high-
resolution mass spectrometry (28). A quantitative phospho-site
(P-site) analysis has the potential to provide a direct readout of
kinase activity, elucidate novel mechanisms driving resistance,
and guide the selection of therapies for validation in cell and
animal models (29, 30). Previously, Old et al. reported ~90 P-
sites that were regulated in a melanoma cell line in response to
short-term MKK1/2 inhibition and Girotti et al. screened the
phosphoproteome of A375 cells in a model for in vitro acquired
drug resistance (31, 32). Both studies identify changes in the
intensity of P-sites in signaling and cytoskeletal regulators and
support the co-inhibition of specific kinase signaling (EGFR-SRC
and SFK-STAT3) to provide therapeutic efficacy in drug resis-
tance (32). To add to this work, we have developed and applied
a simple and reproducible label-free quantitative phosphopro-
teomic procedure and analyzed an in vitromodel of acquired drug
resistance in melanoma cell line LM-MEL-28. The abundance of
2230 P-sites was measured by high-resolution mass spectrometry
and correlated with the abundance of 3556 unmodified proteins
to provide a more accurate determination of kinase activity.
Kinase-substrate databases (Phosphosite.org, cell signaling) and
motif analysis (NetworKIN) of the flanking linear amino acid
sequences predicted several regulatory kinases that aremost likely
to be responsible for differential phosphorylation detected during
long-term exposure to BRAF inhibition in LM-MEL-28. Key regu-
latory sites that control actin and microtubule-based cytoskeleton
and cellular GTP/GDP ratio exhibited large changes in phospho-
rylation. Phosphorylation of the melanosome G-protein coupled
receptor (GPCR) OA1 (GP143) indicated a direct role for the
melanocyte maturation pathway. While sites of phosphorylation
of the insulin receptor substrate IRS-2 and IGFR2 indicated novel
points of regulation in the IGF-1R pathway previously identified
to mediate drug resistance in melanoma.
Materials and Methods
Cell Culture and Protein Preparation
The melanoma cell line LM-MEL-28 was selected from the Lud-
wig Institute for Cancer ResearchMelbourneMelanoma Cell Line
Panel (33). LM-MEL-28 was cultured in RPMI 1640 medium
supplemented with 10% (v/v) bovine serum (Life Technologies)
at 37°C in a humidified atmosphere of 5% CO2. Cells were treated
with PLX4720 (Selleck Chemicals) for a 1-month period in 5 µM
PLX4720 to generate a drug resistant line referred to LM-MEL-
28R1. Cells were tested for authenticity by short tandem repeat
profiling according to the ANSI/ATCC ASN-0002-2011 stan-
dards. For phosphoproteomic analysis, six biological replicates
were generated by sub-culture and cells were grown to 80–90%
confluence with the LM-MEL-28-R1 continuously cultured in the
presence of 5 µM PLX4720 and LM-MEL-28 in the presence of
vehicle. Cells were washed three times in PBS and harvested by
gentle enzyme-based release (TrypLE), pooled and centrifuged
at 400 g, cell pellets frozen on dry ice and stored at  70°C.
Cells were lysed by boiling for 5min in 1% (w/v) sodium deoxy-
cholate (Sigma), 50mM triethylammonium bicarbonate (TEAB)
(Sigma), and 1mM MgCl2 (Sigma). Lysates were cooled to 4°C,
sonicated to complete lysis, and DNA was digested by incubation
with benzonase (Sigma) (10,000 units). Lysate were centrifuged
at 20,000 g for 10min and protein amounts determined by
the micro-BCA assay (Pierce). Samples were stored at  80°C.
Mutational testing was performed by MelCarta assay and all cell
lines were tested formycoplasma and appropriate consent from all
patients had been obtained.
Protein Digestion and Phosphopeptide
Enrichment
Five hundred milligrams of total protein lysate were reduced with
5mMDTT (Sigma) for 30min at 60°C and alkylated with 10mM
of iodoacetamide (Sigma) in the dark at room temperature for
30min. Trypsin (Promega) was added at ratio of 1:50 ratio for
18 h at 37°C. Samples were adjusted to 1% (v/v) trifluoroacetic
acid (TFA) (Sigma), 80mg/ml glycolic acid (Sigma), and the
precipitated deoxycholate was removed by centrifugation. Five
milligrams of TiO2 beads (Titanisphere, 10 µm)were washed once
in 0.1% (v/v) TFA, 70% (v/v) acetonitrile (ACN), and 80mg/ml
glycolic acid, added directly to the sample and incubated with
shaking for 1 h. A C8 stage-tip was prepared and washed with
methanol (Sigma), then 0.1% (v/v) TFA, 70% (v/v) ACN, and
80mg/ml glycolic acid (40 µl). TiO2 beads were added to the
Frontiers in Oncology | www.frontiersin.org May 2015 | Volume 5 | Article 952
Parker et al. Phosphoproteome of BRAF inhibitor resistance
C8 stage-tip and tips were centrifuged 1000 g until all liquid
was dispensed. Beads were washed on tip with 300 µl of 0.1%
TFA, 70% ACN, 80mg/ml glycolic acid (300 µl) twice then thrice
with 0.1% (v/v) TFA and 70% (v/v) ACN. Phosphopeptides were
eluted fromTiO2 tip with consecutive 100 µl additions of 1% (v/v)
ammonia (Sigma) with 0, 30, and 50% (v/v) ACN. Samples were
immediately dried and resuspended in 1% (v/v) TFA and 5% (v/v)
ACN for LC-MS/MS.
Isobaric Labeling by Reductive Dimethylation
and Peptide Separation
Proteolytic digestion of 100 µg total protein was carried out as
described above and samples were labeled by reductive dimethy-
lation using formaldehyde isotopologues (34) with slight modi-
fications (35). After labeling, each sample was pooled and 40 µg
separated into six fractions using pH-based strong anion exchange
(SAX) STAGE tips (36) described in Ref. (37).
Mass Spectrometry (LC-MS/MS)
Samples were loaded onto a self-packed 100 µm 3.5 cm reversed
phase peptide trap (Solid core Halo® 2.7 µm 160Å ES-C18,
Advanced Materials Technology) and desalted for 10min with
buffer A [0.1% (v/v) formic acid], peptide separation was carried
out using a self-packed 75 µm 10 cm (Solid core Halo® 2.7 µm
160Å ES-C18, AdvancedMaterials Technology) column. A buffer
B [100% (v/v) ACN, 0.1% (v/v) formic acid] gradient (5–40%
in 120min) was used to elute peptides. Phosphopeptides were
ionized by electrospray ionization and data-dependent MS/MS
acquisition carried out using a Q-Exactive consisting of 1 full MS1
(R= 70K) scan acquisition from 350 to 1500m/z, and 10 HCD
type MS2 scans (R= 15K). Dimethylated peptides were analyzed
on an Orbitrap Elite (Thermo Fisher Scientific) consisting of 1
full MS1 (R= 120K) scan acquired from 350 to 1500m/z, and
10 CID type MS2 scans. On both instruments, monoisotopic
precursor selection, charge state screening, and dynamic exclusion
were enabled, charge states of +1, >4, and unassigned charge
states were not subjected toMS2 fragmentation. Rawmass spectra
were identified using Maxquant 1.3 using a 1% peptide and pro-
tein FDR. Searches were conducted against the uniprot complete
proteome reference database downloaded on June 06, 2014. The
database was supplemented with common contaminants often
found in cell culture and proteomics experiments these were later
removed. Searches specified for tryptic peptides with four missed
cleavages, 7 ppm precursor ion mass tolerance, 0.05Da fragment
ion mass tolerance, fixed modifications of carbamidomethylation
(C), and variable modification of oxidation (M), acetylation (N-
term, protein), and phosphorylation (STY). For phosphopeptides,
quantitation was performed using peptide intensity for modified
(STY) P-sites and for proteins using the protein intensity ratio
from the protein groups detected in the dimethylated data-set gen-
erated byMaxquant (38). Statistical analysis was carried out using
Perseus 1.5.0 (39). Intensities were pre-processed by log2 trans-
formation and checked for normality. To identify differentially
expressed peptides, the Student’s t-test were applied to compare
groups, P values were filtered for the effect of multiple hypothesis
testing using the FDR method (<5%). The mass spectrometry
proteomics data have been deposited to the ProteomeXchange
Consortium (40) via the PRIDE partner repository with the
dataset identifier PXD002079.
Phosphosite Localization and Kinase Assignment
To localize modifications search results were processed using
Maxquant that generates a score and probability function to assign
confidence to amino acidmodification location based on available
peak depth present in MS/MS spectra. Upstream kinases were
putatively assigned using the NetworKIN algorithm (41) and
Phosphosite database (42).
Viability Assays
Cell lines were seeded in 96-well plates at 5000 cells/well in tripli-
cate for each drug treatment and time point. After 2 h, cells were
treated with dilutions 5 µM for vemurafenib (PLX4072) alone or
in combination with 1.25 or 2.5 µM of the CK2 inhibitor (CX-
4945). After 72 h, cell viability for each cell line was assessed by
Presto Blue Assay (Life Technologies).
Results
Phosphoproteome Analysis of In vitro Drug
Resistance
Figure 1A outlines themethodology taken to investigate the phos-
phoproteome of drug-exposed melanoma cells. To model drug
resistance, a BRAF(V600E) mutant cell line (LM-MEL-28) was
cultured inmedia containing 5 µMof the selective BRAF inhibitor
PLX-4720 for 1month to generate the stable cell line, LM-MEL-
28R. The resistant line LM-MEL-28R was threefold less sensitive
to the growth inhibitory effects of PLX4720 than the parental
line LM-MEL-28 as shown in a viability assay (Figure 1B). For
phosphoproteomic and proteomic analysis, protein extracts were
generated, digested with trypsin, and then phosphopeptides were
enriched by micro-column based TiO2 chromatography analyzed
by LC-MS and total peptides labeled by reductive dimethylation
using light and heavy isotopes, mixed, separated by SAX chro-
matography and analyzed by LC-MS; all steps were performed in
triplicate. LC-MS identified 3162 unique phosphopeptides (S,T,Y)
sequences, mapping to 1164 distinct protein groups and 16,713
none-phosphorylated peptide spectral matches mapping to 3556
protein groups at a FDR of 1% using Maxquant; 836 phosphopro-
teins (72%) had dual P-site and protein quant estimates providing
added confidence in this dataset for detecting changes in phospho-
rylation occupancy (Figure 1C; Tables S1–S3 in Supplementary
Material). The intensity of all phosphopeptides within replicates
exhibited a strong positive correlation and low variance (R2 of
0.75–0.84 and CV 27.26–28.28%). Using a probability function,
76% (2395 of 3162) p[S], p[T], p[Y] sites could be localized
with high confidence (>75%) by MS/MS spectra (Figure 1D;
Table S3 in Supplementary Material). The intensity of all peptides
containing P-sites was used to compare cell populations initially,
while Class 1 (>75%) was used for assigning kinase–substrate
relationships.
Phosphorylation of the MAPK1 Pathway
Because the MAPK1 pathway is often at the center of acquired
drug resistance to BRAFi, we first examined the relative abun-
dance of P-sites in MAPK1, RB1, and CDK1/2, which can provide
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FIGURE 1 | Phosphoproteomic analysis of in vitro drug resistance in
melanoma cells. (A) The melanoma cell line LM-MEL-28 BRAF(V600E) was
exposed to BRAF inhibitor PLX4072 for 30 days to generate LM-MEL28R cell
population. Proteins were extracted, digested, and TiO2 enrichment (for
phosphopeptides) or labeled by reductive dimethylation, separated by tip-based
strong anion exchange (SAX) chromatography, and analyzed by LC-MS and
Maxqaunt. (B) The viability of LM-MEL-28R and LM-MEL-28 cells when grown
in BRAFi was compared after 3 days (error bars are SD). (C) Venn diagram giving
the number of P-sites and proteins identified by LC-MS, overlap is calculated
where quantitation for P-sites and protein has been determined. (D) Histogram
of probability values obtained from Maxquant for P-site localization accuracy,
dotted line indicates the >0.75 cut-off used for kinase enrichment analysis.
a measure of MAPK1 signaling (Figures 2A–C). Regulatory P-
sites [MAPK1 (T185), RB1 (T821)] and the inhibitory site in
CDK1/2 (T/14Y15) were quantified and increased in abundance
in LM-MEL-28-R, indicating reactivation/modulation of MAPK1
signaling had taken place in LM-MEL-28R despite continued
BRAFi (Figures 2A–C). LC-MS data also provided a site-specific
quantitative measure of protein phosphorylation for MAPK1 and
RB1 and can thus indicate the activity of the regulatory kinases.
To demonstrate this further, we selected the heavily phospho-
rylated protein, sequestosome-1 (SQSTM1), a known substrate
of CDK1 (S269, S272) and demonstrate divergent site-specific
protein phosphorylation is detectable. P-site intensity decreased at
sites T269, S272 and increased at site S361 providing a snap shot
of the activity of multiple kinase and/or phosphatases that target
this protein (Figure 2D).
Proteome of Drug Resistance
To more accurately determine change in phosphorylation after
BRAF drug resistance the proteome of LM-MEL-28 and LM-
MEL-28R1 cell populations was compared using isotope coded
quantitative proteomics and LC-MS (Table S3 in Supplementary
Material). Analysis of these data alone indicated widespread reg-
ulation of protein biosynthesis occurs during the development
of resistance to BRAFi. Using a twofold cut-off, the majority of
proteins were found down-regulated (317) and fewer (151) up-
regulated. 1-D gene set enrichment analysis using the log2 ratio
and the Kyoto Encyclopedia of Genes and Genomes (KEGG, http:
//www.genome.jp/kegg/) database reflects this and is reported in
Table 1 andTable S4 in SupplementaryMaterial). Down-regulated
processes indicate major reprograming of metabolic pathways for
amino acid metabolism and energy transducing systems (TCA
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FIGURE 2 | Phospho-site analysis of MAP kinase pathway output. (A–D) The log2 intensity of key P-sites from proteins that function in and downstream of the
MAPK01 (ERK1/2) pathway signaling are plotted and analyzed using a Student’s t-test (error bars are SD).
and Glycolysis). Up-regulated processes indicate changes in pro-
cesses controlling DNA metabolism and the cell cycle.
Phosphorylation Dynamics in Drug Resistance
With estimates of both P-site and protein effect for drug sensi-
tive and resistant populations of LM-MEL-28, we subtracted the
protein effect to determine more accurately changes in the rate of
phosphorylation at significant sites. Protein quantitative estimates
for 2895 sites (~72%) were available and using the following
equation (Phospho rate = log2 Phospho  log2 Protein) specific
post-translational activity (kinase or phosphatase) was inferred.
Figure 3 is an x/y scatter plot of the significant P-sites (n= 148,
Student’s t-test FDR corrected P< 0.05) where x is log2 P-site
ratio (R1/S1) and y is log2 protein ratio (R1/S1). Data were well
correlated indicating a large effect of protein abundance on P-site
abundance (Pearson’s R2= 0.6, P< 0.0001) (Figure 3A). Forty-
seven accurately localized (P< 0.75) P-sites were differentially
regulated by a minimum of twofold after protein abundance was
subtracted, and these were selected for kinome analysis using
Phosphosite.org and NetworKIN databases (41, 42) (Table 2).
Seventeen sites originated from singly phosphorylated peptides,
30 sites were from 15 doubly phosphorylated peptides, of which
5 had a second site where the P-site localization was ambiguous
(Class 2) (Table S5 in Supplementary Material). All accurately
localized sites (Class 1) were used for further analysis, and it
was accepted that for sites originating from the same peptide
the quantitative value would amount to the sum of regulation at
each site.
Kinase Enrichment Analysis
Using the phosphosite.org and NetworKIN databases, regulatory
kinases for 29/46 P-sites could be assigned and are reported
in Table 2 and Tables S3 and S5 in Supplementary Material.
Of the 46 P-sites, 11 were in key cytoskeletal regulators and
kinase predictions were available for 7 of these sites. For exam-
ple, myosin regulatory light chain, MLC12A/B/9 (T18 and S19)
destrin/cofilin (S3) predicts the activity of ROCK1 and LIMK1/2
protein kinases (Figure 3B). P-sites in three distinct guanidine
exchange factors (GEF’s 11, 40, and 1)were also regulated by phos-
phorylation and S35 in GEF40 is putative substrate for the p21-
associated kinase PAK4 (Figure 3C; Table 2). Phosphorylation
of two microtubule-associated proteins (MAPs) increased at six
sites (Figure 3D). Here, sites S2019, S2022 predicted the activity
of CK1A on MAP1A and S1793, S1797 are putative substrates for
GSK3β onMAP1B. Other sites of note for which kinase–substrate
predictions were determined included two MAPK1 substrates
TPR (S2155) and PPP2R2A (S692). Sites in the key signaling
molecules insulin receptor substrate 1 (IRS1, S736), the insulin-
like growth factor 2 receptor/cation-independent mannose-6-
phosphate receptor (IGF2R/CI-MPR, S2484), and protein kinase
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TABLE 1 | 1-D gene enrichment analysis.
KEGG pathway name Proteinsa Medianb Benj.
Hoch. FDR
Mismatch repair 14 0:50 3.4E-03
DNA replication 24 0:34 1.3E-04
Nucleotide excision repair 21 0:26 4.6E-04
Cell cycle 40 0:22 3.5E-04
Huntington’s disease 97  0:37 3.3E-03
Oxidative phosphorylation 73  0:40 7.2E-04
Alzheimer’s disease 87  0:41 3.3E-03
Parkinson’s disease 76  0:41 3.0E-04
Glycolysis/gluconeogenesis 34  0:48 4.6E-03
Ribosome 72  0:52 1.2E-08
Cardiac muscle contraction 25  0:55 6.6E-04
Peroxisome 30  0:59 2.9E-03
Aminoacyl-tRNA biosynthesis 30  0:60 3.5E-04
Fatty acid metabolism 24  0:60 1.6E-03
Citrate cycle (TCA cycle) 27  0:61 2.2E-03
Valine, leucine, and isoleucine
degradation
26  0:62 4.1E-04
Pyruvate metabolism 27  0:63 1.4E-03
PPAR signaling pathway 22  0:67 2.6E-03
Tryptophan metabolism 14  0:75 3.3E-04
aNumber of proteins annotated with the KEGG pathway.
bMedian log2 fold change for proteins annotated within the KEGG pathway.
C (PKC, S497) indicated activity ofGSK3α/β, CK2A, andPDHK1,
respectively. Nestin (S680) and sequestosome-1 (T269, S272)
decreased in phosphorylation and are predicted to be substrates of
CDK1, consistent with the increase in inhibitory phosphorylation
of CDK1 (Y15/T14) measured. Finally, Casein kinase 2 alpha
(CK2A)was predicted to regulate six sites, four of which increased
in abundance for proteins that function in core processes of
DNA replication and damage responses [MCM3 (S711, S672)
and HERC2 S2928] and protein translation (RPLP1/2, S104/105)
(Table 2).
Meta-Analysis
Recently, Girotti et al. identified major regulation of phospho-
proteins involved in cytoskeletal and cell invasion gene ontology
and interaction modules occurs in melanoma cells with acquired
BRAFi resistant in vitro (32). To investigate our results in the
context of this and other data-sets a meta-analysis of datasets
including Girotti et al. and Old et al. (a measure of short-term
BRAFi in melanoma) was completed Table S7 in Supplementary
Material (31, 32). Several sites in cytoskeletal proteins [e.g., Nestin
(S680/768), Cortactin (S405) MAPB1 (S1793)] were commonly
regulated in both our and the Girotti et al. (32) datasets. Less
overlap is observed with the Old et al. screen, with only Cortactin
(S405/S401) andNES (S768) regulated in all three data-sets. Addi-
tionally, we compared our data to an shRNA screen by Sun et al.
for factors that influence the expression of EGFR in acquired drug
resistance (13). Both SOX-10 and MTA2 were identified in the
screen and both aremeasured in our proteomic data.We observed
no change in SOX-10 protein expression, but an increase inMTA2
expression in drug resistance cells (Figure S1 in Supplementary
Material).
Drug Resistant Cells are Sensitive to CK2
Co-Inhibition
Based on the measured increase in phosphorylation of several
putative CK2 sites in LM-MEL-28R and our previous finding
that CK2 inhibition is synergistic with BRAF inhibition in
BRAF(V600E) mutated cells (43), we tested whether LM-MEL-
28R was sensitive to CK2 inhibition. Figure 4 demonstrates
that the resistant line was sensitive to co-inhibition with CK2
inhibitor CX-4595 and that this inhibition was beyond what was
observed for CK2 alone in the drug sensitive LM-MEL-28. A
quantitative reduction in cell growth over several concentrations
of inhibitor (<50% at 2.5 µM and <90% at 5 µM) was observed
in LM-MEL-28R.
Discussion
Changes in the phosphoproteome of a BRAF(V600E) mutant
melanoma cell line that occur after the development of drug
(PLX4720) resistance in vitro are described here. Using a sin-
gle step phosphopeptide enrichment followed by LC-MS analy-
sis and label-free quantitation using the freeware Maxquant, we
accurately detected and measured ~2700 phosphorylation events
and 3556 proteins. Initially, we quantitated the viability of both
unexposed and drug resistant populations in the presence of
BRAFi. We observed that although viability was reduced after
drug adaption, stable growth was maintained and cells were able
to propagate in the presence of 5 µMPLX4720.Our in vitro system
provided a suitable model to measure phosphorylation in drug
resistance in vitro; and through kinases landscape analysis the
activity of several kinases regulating these events was predicted.
Drug resistance in melanoma often occurs through reacti-
vation of MAPK signaling despite continued exposure to the
inhibitor (10). Through selective analysis of regulatory P-sites in
the MAPK1 signaling pathway (ERK1/2) and downstream cell
cycle regulators (RB1 and CDK1), our cell model was consistent
with MAPK reactivation in resistant cells despite exposure to
BRAFi. With this data set, we next investigated the relationship
between protein phosphorylation and protein abundance. Amea-
sure for protein abundance was available for ~72% of measured
P-sites. The measure for protein was based upon all identified
unmodified peptides mapping to the same protein group as the P-
site-derived peptide spectral match. This measure could account
for the dominant effects of protein metabolism (synthesis and
degradation) often observed in cells during long-term adaptive
responses. As expected, the abundance of the majority of P-sites
closely followed that of protein expression, with only a small
subset (46 P-sites) exhibiting changes in abundance that could
not be accounted for by changes in the rate of protein turnover.
The most likely explanation for this divergence is the activity
of kinase(s) or phosphatase(s) with specific regulatory functions
in cellular adaption to BRAF inhibition. Focusing on kinases
where the most probable enzyme–substrate relationship(s) can be
mapped, potential regulatory mechanisms were identified and are
discussed below and summarized in Figure 5.
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FIGURE 3 | Phosphorylation rate analysis. (A) Correlation of metrics for
P-site effect with protein abundance effect measured between drug
sensitive and resistant cell populations. Green=P-site effect
twofold>protein effect. Red=P-site effect twofold<protein effect. Log2
intensity of P-sites and total protein for key cytoskeletal regulators
(B) myosin and destrin, (C) guanidine exchange factors (11, 40, and 1), and
(D) microtubule-associated proteins 1A and 1B analyzed using a Student’s
t-test (error bars are SD).
Drug Resistance Induces De/Phosphorylation of
the Cytoskeleton Regulators
Cytoskeletal changes are central to the phenotypic transitions
that occur in tumor progression, altering invasiveness, metastasis,
and resistance to therapy and this was reflected in our data. P-
sites that are key regulatory residues in proteins controlling both
actin and microtubule-based filaments were altered beyond pro-
tein metabolic control. Destrin (actin-depolymerization factor,
ADF) is responsible for actin stability (44) and Ser-3 can be
phosphorylated by LIM domain kinase 1 and 2 (LIMK1/2) to
induce cytoskeletal reorganization to form stress fibers, mem-
brane blebs and alter cell adhesion through the formation of F-
actin in non-muscle tissue (45, 46). Myosin light chain (12A/B/9)
phosphorylation of S19 and T18 provide evidence for increased
activity of several up-stream kinases [myosin light chain kinase
(MLCK), Rho-associated kinase (ROCK), citron kinase, leucine
zipper interacting kinase ZIPK/DAPK3, and CDC42 binding
kinase]. Functionally, phosphorylation of S19/T18 alleviates auto-
inhibition of the MYLC globular heads and promotes interaction
with actin to form bipolar filaments (47). The activating signals
for this are diverse, ROCK2 is activated by the small GTP-binding
protein RhoA, which is dependent on the activity of GEFs (48,
49). In the resistant cell population, a drop in phosphorylation
of three different GEF’s, including S35 in GEF11 was measured.
Phosphorylation ofGEF11 by the Cdc42 effector kinase PAK4 and
p38 MAPK both lead to a drop in GEF activity (50, 51). Kinase
enrichment analysis predicted a C-terminal site S35 to be a target
for PAK4, indicating a novel site where PAK4 may regulate GEF
activity in drug resistant cells. In themicrotubule-based cytoskele-
ton, reduced phosphorylation of MAPs indicated altered tubule
stabilization and several sites near microtubule binding domains
could influence the tethering of cargo for transportation (52). P-
site S1793 and S1797 in MAP2A are putative sites for GSK3-β.
GSK3-β activity couples extra-cellular matrix (ECM) signaling to
the actin/microtubule cytoskeleton during cell migration (53).
The regulation of cytoskeletal dynamics by Rho/ROCK and
GEF signaling is a key driver of the phenotypic transitions or
switching that can change the migratory phenotype of cells (54).
In melanoma, transcriptional networks that have roles in mes-
enchymal and amoeboid transitions alter during metastasis and
response to therapy (55). These changes may contribute to the
intrinsic invasive phenotypes that have been observed in response
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TABLE 2 | Regulated phosphosites in drug resistant cells and the prediction of putative regulatory kinases.
Protein names Gene names P-site Diffa R PhosphoSitePlus kinase NetworKIN
Protein kinase C alpha type PRKCA T497 2:21 + PDHK1
Serine/threonine-protein phosphatase 2A regulatory
subunit B” subunit alpha
PPP2R3A S692 1:41 MAPK3, MAPK1,
CDK1
Myosin regulatory light chain 12B MYL12B S25 2:74 + ILK; DLK; DAPK1; ROCK1; AurB;
smMLCK; DAPK3; CAMK1A; CRIK;
MRCKA; PKCA; PAK1
Myosin regulatory light chain 12B MYL12B T24 2:74 + ILK; DLK; ROCK1; smMLCK; DAPK3;
CRIK
ROCK2
G-protein coupled receptor 143 GPR143 S343 1:28
Destrin DSTN S3 2:29 + LIMK2; LIMK1; TESK1
40S ribosomal protein S6 RPS6 S236 2:49 + PKCD; p90RSK; p70S6K; RSK2 p70S6K
Nucleoprotein TPR TPR S2155 1:59 MAPK1
Choline-phosphate cytidylyltransferase A PCYT1A S347 1:66
E3 ubiquitin-protein ligase HERC2 HERC2 S2928 1:32 CK2alpha
Choline-phosphate cytidylyltransferase A PCYT1A S343 1:59
DNA replication licensing factor MCM3 MCM3 S756 1:16 CK2alpha
DNA replication licensing factor MCM3 MCM3 S717 1:15 CK2alpha
60S acidic ribosomal protein P1 RPLP1 S104 1:92 CK2alpha
60S acidic ribosomal protein P2 RPLP2 S105 1:80 GRK2, CK2alpha
Insulin receptor substrate 2 IRS2 S736 1:34 GSK3alpha,
GSK3beta
Choline-phosphate cytidylyltransferase A PCYT1A S331  1:25
ATP-dependent RNA helicase DDX24 DDX24 S82  1:31 Chk1
Ras-related GTP-binding protein C RRAGC S95  1:25
Ankyrin repeat and SAM domain-containing protein 1A ANKS1A S663  1:53
Septin-9 SEPT09 S85  1:24 CK1delta
CLIP-associating protein 1 CLASP1 S415  1:75 NEK2, CaMKIIalpha
C-Jun-amino-terminal kinase-interacting protein 4 SPAG9 S730  1:25
C-Jun-amino-terminal kinase-interacting protein 4 SPAG9 S733  1:25
Rho guanine nucleotide exchange factor 40 ARHGEF40 S262  1:80
MAP7 domain-containing protein 1 MAP7D1 S113  1:69
Niban-like protein 1 FAM129B S646  1:04
Sequestosome-1 SQSTM1 S272  1:40 + CDK1 MAPK3
60S ribosomal export protein NMD3 NMD3 T470  1:81
Niban-like protein 1 FAM129B S641  1:23
Sequestosome-1 SQSTM1 T269  1:62 + CDK1 MAPK3
Syntaxin-12 STX12 S142  1:87
E3 ubiquitin-protein ligase NEDD4L S308  1:06 PDHK1, GSK3beta
Rho guanine nucleotide exchange factor 11 ARHGEF11 S35  1:70 PAK4
E3 ubiquitin-protein ligase NEDD4L S307  1:30 + PKACA; SGK1 TGFbR2
Rho guanine nucleotide exchange factor 1 ARHGEF1 S919  2:42
Microtubule-associated protein 1A MAP1A S764  1:46
Microtubule-associated protein 1A MAP1A S765  1:46
Microtubule-associated protein 1A MAP1A S1913  1:89
Cation-independent mannose-6-phosphate receptor IGF2R S2484  2:74 CK2A1 CK2alpha
Nestin NES S680  2:31 CDK1, CDK5
Microtubule-associated protein 1B MAP1B S1793  2:05 GSK3beta
Microtubule-associated protein 1B MAP1B S1797  2:05 GSK3beta
PDZ and LIM domain protein 4 PDLIM4 S112  2:08
Microtubule-associated protein 1A MAP1A S2257  3:85 CK1alpha, CK1delta
Microtubule-associated protein 1A MAP1A S2260  3:85 CK1alpha, CK1delta
aLog2 fold change corrected for protein effect (see text), R (known regulatory site).
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FIGURE 4 | CK2i of the drug resistant cell line (LM-MEL-28-R1). The
effects of co-inhibition with the CK2 inhibitor CX-4945 and BRAFi (PLX4072)
on proliferation of the drug resistant cell population LM-MEL-28-R1 were
quantitated by viability assay, analyzed using a Student’s t-test (error bars are
SD).
to inhibitor therapy (25, 32). ROCK1 and 2 promote myosin
phosphorylation and actin fiber formation to drive amoeboid
movement, where cell membranes undergo extensive blebbing
allowing cells to deform and pass through voids in the surround-
ing matrix (56). Co-inhibition of ROCK signaling has recently
been shown to enhance the anti-proliferative effect of the BRAFi
PLX4720 and supports our observation that drug resistant pop-
ulations utilize ROCK signaling as a pro-survival mechanism
(57). Through a meta-analysis of our results with other drug-
exposed cell models (31, 32), a clear functional role can now
be confirmed for the phosphorylation of proteins that function
in the cytoskeleton. However, this analysis revealed that only
20/145 P-sites were shared between our data and that of Girotti
et al. (32). This discrepancy could be explained by the myriad of
possiblemechanisms that canmediate drug resistance and is likely
to depend on tumor genotype, heterogeneity, and locale; where
each generates a unique cytoskeletal organization of maximum
fitness. Outside of biological variation, technical differences in
data generation and analysismay underlie the inconsistency in the
P-sites identified. However, in Girotti et al., despite differences in
methodology and only a twofold cut-off being applied to assign
significance, of the sites that do overlap the majority of P-sites
(13) exhibit a similar direction of regulation. While carrying out
this meta-analysis, we also compared the proteomic data to the
results of an shRNA screen for mechanisms of EGFR-based drug
resistance in melanoma. Here, we identified MTA2 but not SOX-
10 protein expression as altered in drug resistant cells. In Sun
et al. (13), MTA2 is ruled out as a false-positive mediator by a
targeted approach. These data provide an indication that LM-
MEL-28, does not acquire BRAFi resistant through expression
of EGFR receptor via SOX-10 attenuation; and could further
explain the discrepancy in regulated P-sites with Girotti et al.,
where EGFR signaling is required for growth of the resistant cell
population (32).
Melanosome Signaling Through G-Protein
Couple Receptor-143 (OA1)
G-protein-coupled receptors can generate signals key to the devel-
opment of resistance to BRAF inhibitor therapy (58). Here, we
identified novel sites of phosphorylation (S331/S343) in theGPCR
143, also known as ocular albinism type 1 (GPR143/OA1), that
increased in BRAFi resistant cells (Table 1; Figure 5). OA1 is a
pigment-cell specific G-protein receptor for tyrosine, -DOPA,
and dopamine it also localizes to intracellular melanosomes and
forms a key component of melanosome biogenesis and trans-
port (59–61). OA1 regulates expression of the MITF, sustaining
its expression and promoting melanocyte differentiation (62).
Oncogenic BRAF can suppress MITF expression preventing nor-
mal melanocyte differentiation and promoting transformation
to a de-differentiated proliferative state (63). In GPR143/OA1,
S331/S343 reside in the C-terminal cytoplasmic domain andwhile
no kinase prediction was assigned, phosphorylation here could
drive the classical recruitment of beta-arrestins and lead to inac-
tivation of G-protein signaling by OA1 leading to further de-
differentiation observed in drug resistant tumors (64). OA1 also
signals through the actin/microtubule cytoskeleton to regulate the
transport of melanosomes from the perinuclear region to the cell
periphery and could in-part drive phosphorylation dynamics of
the cytoskeleton indicated above (59). Finally, S331 is directly
adjacent to a two amino acid “WE” domain vital for the correct
localization of OA1 protein to the melanosome (65). Mutation
of WE>AA redirects OA1 to the plasma membrane (65). The
role of OA1 phosphorylation in protein localization, melanosome
and cytoskeleton signaling and how this facilitates drug resistance
remain to be tested.
Key P-Sites in Known Signaling Nodes Reflect
MAPK1 Reactivation
T497 in protein kinase C alpha (PKCα) increased in expression
and phosphorylation in drug resistant cells. T497 in PKCα is
located in the activation loop and phosphorylation is essential
for full catalytic activity of PKCα (66). Phosphorylation of T497
by PDPK1 (PDK1) is classically dependent on phosphatidyli-
nositol metabolism and PI3K activation induced by GPCR or
TRK signaling (Figure 5). PKCα activity in melanoma is highly
context dependent with roles in both oncogenesis and growth
suppression (67). PKCα can contribute to activation of theMAPK
pathway through direct phosphorylation of RAF substrates to
activate ERK, or promote the c-Jun N-terminal kinase (JNK)
MAP kinase pathway through association with RACK1 (68, 69).
RACK1 shuttles PKCα to target the stress-related MAPK JNK for
phosphorylation leading to constitutive activation of p38 MAPK
signaling (69). Interestingly, we measured dephosphorylation of
S730/733 in SPAG9 (JIP4), a scaffold protein involved in the
spatial organization of MAP kinases and a mediator of c-Jun
N-terminal kinase. The meta-analysis of Girotti et al. (32) sup-
ported this finding and while kinases/phosphatases able to reg-
ulate SPAG9 S730/733 phosphorylation remain unreported our
data indicates that regulationmay be key to the rewiring ofMAPK
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FIGURE 5 | Network cartoon summarizing the prominent differences in phosphorylation measured between BRAFi sensitive and resistant cell
populations.
signaling in cells adapted to BRAFi. A further mechanism able
to reactivate ERK1/2 signaling in BRAFi resistance was indicated
by the increased phosphorylation of the ERK/1/2 substrate TPR
at S2155 (Table 1). TPR is a nuclear pore complex protein and
chromatin regulator that in response to ERK1/2 phosphorylation
can bind and localize ERK1/2 to chromatin (70). During short-
term exposure to BRAF and MEK inhibitors phosphorylation of
TPR at S2155 reduces in BRAF(V600E)mutant cell lines (43). The
recovery of TPR phosphorylation in the face of chronic BRAFi
appears to be associated with the re-establishment of MAPK
nuclear signaling in drug adapted cells.
Evidence for potential upstream mechanisms for ERK reac-
tivation is provided by a change in phosphorylation of insulin
receptor substrate (IRS2), a downstream effector of insulin-like
growth factor receptor 1 (IGF-1R). IGF-1R signaling in cancer
cells results fromup-regulation of the receptor or its ligands (IGF-I
and IGF-II) and contributes to the emergence of chemotherapeu-
tic resistance. Insulin receptor substrate (IRS1/2) proteins trans-
mit oncogenic signals through PI3K and ERK signaling modules
(Figure 5). IRS1/2 also mediate the termination of IGF-IR signal-
ing and resistance to PI3K inhibitors occurs through a reduction
in this feedback inhibition [reviewed in Ref. (71)]. We measured
phosphorylation of IRS2 at two sites, (i) S736 confidently localized
and predicted to be regulated by GSK-3α/β and (ii) an ambiguous
P-site (either S730/731/735/740 or Y742) in the same peptide. A
lack of clarity for the position of the second site makes it difficult
to predict, which kinase(s) may be responsible for the regulation
that we observed. However, phosphorylation of IRS2 represents
a key signaling process where cells become reprogramed through
PI3K to activate PDK1-PKC/PKB(AKT) or throughGRB2-SOS to
activate the Ras-MAPK pathway directly (Figure 5) (72). IGF-1R
has been shown to be up-regulated in drug resistantmelanoma cell
lines previously (12). Recently, IRS2 was also found up-regulated
in BRAFi (PLX4032) resistant tumors and blocking or eliminating
IRS or subsequent PI3K-mediated signaling may provide thera-
peutic potential (12, 73). More specifically, IRS-2 is a target of
miR-7-5p found down-regulated in melanoma (74). miR-7-5p
down-regulation is associated with increased cell migration and
metastasis, and using RNA interference (RNAi) IRS-2 was shown
to regulate this phenotype through the PKB/AKT signaling node
(74, 75). In support of a role for IGF signaling, a decrease in the
phosphorylation of a CK2 site (S2484) in the cytoplasmic domain
of the insulin-like growth factor receptor II (IGFR2) known also as
the CI-MPR receptor was detected in BRAFi drug resistant cells.
This protein acts as both the receptor for IGF2 and mannose-6-
phosphate and is implicated in both G-protein signaling and the
targeting of lysosomal enzymes. In CHO cells, phosphorylation of
this site regulates changes in the trafficking of the receptor in the
Golgi-network (76) and down-regulation of plasma membrane
IGFR2 is associatedwith increased signaling through IGF-R1 (77).
This study demonstrated a simple and effective approach to
detect kinase activity important in the transition of cells from
a BRAF sensitive to BRAF resistant phenotype. Once detected
these kinase present themselves as potential targets for future
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co-therapies. During our analysis, we detected increases in the
phosphorylation and abundance of proteins involved in processes
related to DNA metabolism. Several of these sites were substrates
for CK2A, and we tested if long-term exposure to BRAFi provided
protection from the synergistic inhibitory effects of protein kinase
CK2A–BRAF co-inhibition previously observed in BRAF(V600E)
mutant melanoma (43). This was not the case with an additive
effect (>50%) being observed in both parental and resistant popu-
lations, suggesting that this drug combination could be effective in
reducing the emergence of resistant cell populations.We have pre-
viously demonstrated that CK2 plays an important role in priming
the activity of Akt through phosphorylation at S129, and that
controlling CK2 activity is an effective strategy in preventing cell
growth in BRAF melanoma and BRAF thyroid carcinoma (43).
Notwithstanding the importance of Akt-driven growth pathway,
CK2 is a ubiquitous serine/threonine kinase and in the nucleus
plays an important role in modulating DNA-damage and repair
machinery (78, 79); it is likely that the inhibitory effect of blocking
CK2 leads to wide-spread modulation in numerous other path-
ways that support cell proliferation. Understanding the mecha-
nistic significance of how CK2 regulates these other pathways in
melanoma needs ongoing research.
Conclusion
A central paradigm of acquired drug resistance in BRAF mutant
melanomas is the reactivation of MAPK signaling (10). In this
work, a quantitativeMSmethodmeasuring both the phosphopro-
teome and proteome was developed and implemented to describe
novel phosphorylation-based signaling events in cells after this
transition in vitro. We identified increased MAPK01 phospho-
rylation alongside well-known and novel protein phosphoryla-
tion events driven by this and other kinases. Regulation of key
substrates in Rho/ROCK signaling axis provided evidence for
cytoskeletal rearrangements able to facilitate a phenotypic switch
in cell motility that evolve during BRAFi therapy. Importantly,
our study provided evidence for signaling events in several pro-
teins (IGFR2, IRS1, PKC, and GEFs) associated with established
pathways of drug resistance in melanoma and other cancers (12,
80). Phosphorylation of IRS1 re-enforces the importance of IGF
signaling in drug resistant melanoma as a valid target for co-
therapy. Novel sites identified indicate new and untested mecha-
nisms able to promote cell survival and these require confirmation
in vivo. The diversity of drug resistance mechanisms discovered
in melanoma so far indicates a need to develop an individual-
ized approach to multi-targeted cancer treatment. TheMS-driven
phosphoproteomic method described here can be readily applied
to the analysis of tumors biopsied before, during, and after treat-
ment to provide a direct readout for kinases that are drug-able
targets in relapsed patients.
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